Drug Design, Development and Therapy

Open Access Full Text Article

CORRIGENDUM

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]

Mustacchi G, De Laurentiis M. *Drug Des Devel Ther*. 2015;9:4303–4318.

On page 4315, Disclosure section, "This work was supported by an unconditional grant from Editree editors, Italy, and both authors received a fee. Giorgio Mustacchi receives honoraria from Roche, Celgene, and EISAI. Michelino De Laurentiis receives honoraria from Roche, Celgene, EISAI, Novartis, and AstraZeneca. The authors report no other conflicts of interest in this work." should have read "The authors report no conflict of interest with this work".

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal

http://dx.doi.org/10.2147/DDDT.S97778

Drug Design, Development and Therapy 2015:9 5669

5669

© 2015 Mustachi and De Laurentiis. This work is published by Dove Medical Press Limited, and Licensed under Creative Commons Attribution — Non Commercial (unported, v3.0) permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited, Information on how to request permission may be found at: http://www.dovepress.com/permissions.php